Axsome Therapeutics Provides Update On The New Drug Application For Axs-14 For Fibromyalgia
June 9 (Reuters) - Axsome Therapeutics Inc AXSM.O:
AXSOME THERAPEUTICS PROVIDES UPDATE ON THE NEW DRUG APPLICATION (NDA) FOR AXS-14 FOR THE MANAGEMENT OF FIBROMYALGIA
AXSOME THERAPEUTICS INC - RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR AXS-14
AXSOME THERAPEUTICS INC - FDA FINDS NDA FOR AXS-14 INSUFFICIENTLY COMPLETE FOR REVIEW
AXSOME THERAPEUTICS INC - TO CONDUCT ADDITIONAL CONTROLLED TRIAL FOR AXS-14 IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Intel Stock Has Surged 74% in 2026 and Earnings Land April 23 — Is INTC Still a Buy at $68?

Tradingkey






